^
    BIOMARKER:

    No biomarker

    Associations

    Heatmap
    News
    Twitter
    Trials
    No biomarker
    Juvenile Myelomonocytic Leukemia
    azacitidine
    Sensitive: A1 - Approval
    FDA - 2 days - (New A1)
    No biomarker
    Astrocytoma
    carmustine
    Sensitive: A1 - Approval
    FDA - 6 days - (New A1)
    No biomarker
    Ependymoma
    carmustine
    Sensitive: A1 - Approval
    FDA - 6 days - (New A1)
    No biomarker
    Medulloblastoma
    carmustine
    Sensitive: A1 - Approval
    FDA - 6 days - (New A1)
    No biomarker
    HL
    carmustine
    Sensitive: A1 - Approval
    FDA - 6 days - (New A1)
    No biomarker
    NHL
    carmustine
    Sensitive: A1 - Approval
    FDA - 6 days - (New A1)
    No biomarker
    Glioma
    carmustine
    Sensitive: A1 - Approval
    FDA - 6 days - (New A1)
    No biomarker
    GBM
    carmustine
    Sensitive: A1 - Approval
    FDA - 6 days - (New A1)
    No biomarker
    Multiple Myeloma
    carmustine
    Sensitive: A1 - Approval
    FDA - 6 days - (New A1)
    No biomarker
    Thyroid Gland Carcinoma
    cabozantinib tablet
    Sensitive: A1 - Approval
    Ipsen Press Release - 2 weeks - (New A1)
    No biomarker
    Follicular Lymphoma
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    Novartis Press Release - 2 weeks - (New A1)
    No biomarker
    HCC
    durvalumab + CP-675206
    Sensitive: B - Late Trials
    AstraZeneca Press Release - 3 weeks - (New B)
    No biomarker
    NSCLC
    ONC-392
    Sensitive: B - Late Trials
    GlobeNewswire - 3 weeks - (New B)
    No biomarker
    Ovarian Cancer
    VB-111
    Sensitive: B - Late Trials
    VBL Therapeutics Press Release - 3 weeks - (New B)
    No biomarker
    B Acute Lymphoblastic Leukemia
    AUTO1
    Sensitive: B - Late Trials
    GlobeNewswire - 3 weeks - (New B)
    No biomarker
    AML
    CFI-400945
    Sensitive: B - Late Trials
    Treadwell Therap Press Release - 3 weeks - (New B)
    No biomarker
    Breast Cancer
    abemaciclib
    Sensitive: A2 - Guideline
    ASCO.org - 4 weeks - (New A2)
    No biomarker
    CRC
    GCC19CART
    Sensitive: B - Late Trials
    Innovative Cellular Therap Press Release - 4 weeks - (New B)
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    CMG901
    Sensitive: B - Late Trials
    Keymed Biosci Press Release - 4 weeks - (New B)
    No biomarker
    Gastric Cancer
    CMG901
    Sensitive: B - Late Trials
    Keymed Biosci Press Release - 4 weeks - (New B)
    No biomarker
    Marginal Zone Lymphoma
    zanubrutinib
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    pomalidomide + elotuzumab
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    durvalumab
    Sensitive: A1 - Approval
    No biomarker
    RCC
    nivolumab + cabozantinib tablet
    Sensitive: A1 - Approval
    No biomarker
    Malignant Pleural Mesothelioma
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Mediastinal B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Cancer
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    niraparib
    Sensitive: A1 - Approval
    No biomarker
    Ovarian Cancer
    niraparib
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    niraparib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    brexucabtagene autoleucel
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    NHL
    brentuximab vedotin
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    No biomarker
    Small Cell Lung Cancer
    durvalumab
    Sensitive: A1 - Approval
    No biomarker
    SCCHN
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    Gastric Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    cisplatin + pemetrexed
    Sensitive: A1 - Approval
    No biomarker
    Breast Cancer
    docetaxel + doxorubicin hydrochloride + cyclophosphamide
    Sensitive: A1 - Approval
    No biomarker
    BCC
    fluorouracil topical
    Sensitive: A1 - Approval
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    cisplatin
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    carfilzomib
    Sensitive: A1 - Approval
    No biomarker
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    atezolizumab
    Sensitive: A1 - Approval
    No biomarker
    Small Cell Lung Cancer
    atezolizumab
    Sensitive: A1 - Approval
    No biomarker
    AML
    glasdegib
    Sensitive: A1 - Approval
    No biomarker
    HCC
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    HCC
    bevacizumab + atezolizumab
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    bortezomib + panobinostat
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    bortezomib + pegylated liposomal doxorubicin
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    rituximab
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    tislelizumab
    Sensitive: A1 - Approval
    No biomarker
    Lymphoma
    axicabtagene ciloleucel
    Resistant: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    No biomarker
    B Acute Lymphoblastic Leukemia
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    No biomarker
    Childhood B Acute Lymphoblastic Leukemia
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    No biomarker
    Prostate Cancer
    apalutamide
    Sensitive: A1 - Approval
    No biomarker
    CLL
    rituximab + ibrutinib
    Sensitive: A1 - Approval
    No biomarker
    SCCHN
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    AML
    azacitidine oral
    Sensitive: A1 - Approval
    No biomarker
    NSCLC
    DP
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    TPF
    Sensitive: A1 - Approval
    No biomarker
    Urothelial Cancer
    avelumab
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    SVd
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TPF
    Sensitive: A1 - Approval
    No biomarker
    SCCHN
    TPF
    Sensitive: A1 - Approval
    No biomarker
    AML
    cytarabine / daunorubicin liposomal formulation
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    ciltacabtagene autoleucel
    Sensitive: A1 - Approval
    No biomarker
    Soft Tissue Sarcoma
    olaratumab
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    CLL
    venetoclax + obinutuzumab
    Sensitive: A1 - Approval
    No biomarker
    Rectal Cancer
    FOLFIRI
    Sensitive: A1 - Approval
    No biomarker
    Breast Cancer
    TAC
    Sensitive: A1 - Approval
    No biomarker
    Urothelial Cancer
    sacituzumab govitecan-hziy
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    5-fluorouracil + irinotecan
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    pomalidomide
    Sensitive: A1 - Approval
    No biomarker
    Burkitt Lymphoma
    cyclophosphamide
    Sensitive: A1 - Approval
    No biomarker
    Burkitt Lymphoma
    rituximab
    Sensitive: A1 - Approval
    No biomarker
    Adrenal Cortex Carcinoma
    mitotane
    Sensitive: A1 - Approval
    No biomarker
    Neuroendocrine Tumor
    surufatinib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    rucaparib
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    olaparib
    Sensitive: A1 - Approval
    No biomarker
    CRC
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    Aybintio (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Aybintio (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Onbevzi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    Onbevzi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    rucaparib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    olaparib
    Sensitive: A1 - Approval
    No biomarker
    Peritoneal Cancer
    carboplatin + micellar paclitaxel
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    carboplatin + micellar paclitaxel
    Sensitive: A1 - Approval
    No biomarker
    Prostate Cancer
    histrelin acetate
    Sensitive: A1 - Approval
    No biomarker
    Prostate Cancer
    cabazitaxel
    Sensitive: A1 - Approval
    No biomarker
    Retinoblastoma
    cyclophosphamide
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    orelabrutinib
    Sensitive: A1 - Approval
    No biomarker
    Small Lymphocytic Lymphoma
    orelabrutinib
    Sensitive: A1 - Approval
    No biomarker
    CLL
    orelabrutinib
    Sensitive: A1 - Approval
    No biomarker
    GBM
    Byvasda (bevacizumab biosimilar)
    Sensitive: A1 - Approval